4-[bis(ethoxycarbonyl)methyl]-2-mercapto-6,7-dimethoxyquinazoline | 879403-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-[bis(ethoxycarbonyl)methyl]-2-mercapto-6,7-dimethoxyquinazoline
• 英文别名: diethyl 2-(6,7-dimethoxy-2-sulfanylidene-3H-quinazolin-4-yl)propanedioate
• CAS: 879403-06-2
• 化学式: C₁₇H₂₀N₂O₆S
• 分子量: 380.422
• InChiKey: WHAXLDWKDSWXEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2-chloro-6,7-dimethoxy-quinazolin-4-yl)-malonic acid diethyl ester 在 乙醇 、 硫脲 作用下， 生成 4-[bis(ethoxycarbonyl)methyl]-2-mercapto-6,7-dimethoxyquinazoline
  参考文献：
  名称：

  MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS

  摘要：

  公开号：

  EP1801108B9

文献信息

• Morpholine Compound
  申请人：Tanaka Yoshihito

  公开号：US20070265257A1

  公开（公告）日：2007-11-15

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  化合物的化学式为(1)，其中环A是芳基，可选地具有取代基等；环B是芳烃，可选地具有取代基等；m=0-2；n=1-5；X是键等；Y是键等；Z是氢原子等或其药学上可接受的盐，其水合物或溶剂化物具有对CCR3的亲和力，并可用于治疗和/或预防免疫或炎症性疾病的药物产品。
• Morpholine compound
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US07935700B2

  公开（公告）日：2011-05-03

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  化合物的化学式为（1），其中环A是芳基，可以选择地具有取代基等；环B是芳烃，可以选择地具有取代基等；m = 0-2；n = 1-5；X是键等；Y是键等；Z是氢原子等或其药学上可接受的盐，其水合物或溶剂化物具有对CCR3的亲和力，并可用作治疗和/或预防免疫或炎症性疾病的药物产品。
• MORPHOLINE COMPOUND
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1801108A1

  公开（公告）日：2007-06-27

  A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

  由式（1）代表的化合物 其中，环 A 是可选具有取代基等的芳基；环 B 是可选具有取代基等的芳烯；m=0-2；n=1-5；X 是键等；Y 是键等；Z 是氢原子等，或其药学上可接受的盐、水合物或溶液对 CCR3 具有亲和力，可作为治疗和/或预防免疫性或炎症性疾病的药物产品。
• US7935700B2
  申请人：——

  公开号：US7935700B2

  公开（公告）日：2011-05-03
• MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1801108B9

  公开（公告）日：2013-11-20